News
TLSA
0.6660
+4.06%
0.0260
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 13h ago
Tiziana Life Sciences’ MS Treatment Shows Potential
TipRanks · 22h ago
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
Barchart · 1d ago
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Las Vegas Sands Corp. Shares dipped 6.8% to $46.81 on Thursday. The company reported better-than-expected first-quarter results. AGBA Group Holding Limited shares jumped 148% after the company announced a merger agreement with Triller. Other stocks moving in the mid-day session included 23andMe Holding Co. And Vertex Pharmaceuticals.
Benzinga · 1d ago
Tiziana’s Foralumab Shows Promise for MS Treatment
TipRanks · 1d ago
Weekly Report: what happened at TLSA last week (0408-0412)?
Weekly Report · 5d ago
Tiziana Showcases Foralumab’s Neurotherapeutic Potential
TipRanks · 04/11 11:58
Weekly Report: what happened at TLSA last week (0401-0405)?
Weekly Report · 04/08 09:36
Weekly Report: what happened at TLSA last week (0325-0329)?
Weekly Report · 04/01 09:36
Weekly Report: what happened at TLSA last week (0318-0322)?
Weekly Report · 03/25 09:37
Weekly Report: what happened at TLSA last week (0311-0315)?
Weekly Report · 03/18 09:36
Weekly Report: what happened at TLSA last week (0304-0308)?
Weekly Report · 03/11 09:36
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 55.9% to $0.07 during Tuesday's pre-market session. CASI Pharmaceuticals (NASdaq:CASI) shares rose 47.68% in the pre- market session. Regenxbio (NASDA:RGNX) and Apogee Therapeutics also moved upwards. Losers Lipella Pharmaceuticals and Ekso Bionics Holdings.
Benzinga · 03/05 13:09
Weekly Report: what happened at TLSA last week (0226-0301)?
Weekly Report · 03/04 09:37
Weekly Report: what happened at TLSA last week (0219-0223)?
Weekly Report · 02/26 09:40
Weekly Report: what happened at TLSA last week (0212-0216)?
Weekly Report · 02/19 09:40
UPDATE 2-European, US carmakers race to lower EVs costs as China competition heats up
European, US carmakers race to lower EVs costs as China competition heats up. Major U.S. And European carmakers are pushing hard to cut electric vehicle costs. They are under pressure from lower-cost Chinese competitors. The high cost of EVs has become a barrier to mass adoption.
Reuters · 02/15 13:23
Weekly Report: what happened at TLSA last week (0205-0209)?
Weekly Report · 02/12 09:37
Weekly Report: what happened at TLSA last week (0129-0202)?
Weekly Report · 02/05 09:39
Weekly Report: what happened at TLSA last week (0122-0126)?
Weekly Report · 01/29 09:37
More
Webull provides a variety of real-time TLSA stock news. You can receive the latest news about Tiziana Life Sciences Ltd Com through multiple platforms. This information may help you make smarter investment decisions.
About TLSA
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.